US-based gene therapy biotech Seawolf Therapeutics and Sanofi have signed a multi-target research partnership and exclusive licensing deal worth up to $1.2bn to develop treatments for bleeding disorders and other undisclosed indications.
Seawolf will use the capital to progress candidates built upon its TRIDENT platform. Credit: Gorodenkoff/Shutterstock.com.
Subscribe to our email newsletter
Under the terms of the partnership, Seawolf could receive the funds upon reaching research, development, and commercial milestone payments, alongside tiered royalties on future sales of any therapies resulting from the collaboration.
The alliance coincides with Seawolf emerging from stealth mode with $100m in financing to advance its pipeline of deoxyribonucleic acid (DNA)-based medicines.
This funding total includes seed financing led by founding investor Versant Ventures, followed by a Series A round supported by MPM BioImpact, Novartis Venture Fund, and Versant Ventures.
Other participants in the financing included Alexandria Venture Investments, CRISPR Therapeutics, Eli Lilly and Company, Pathway to Cures, which is the philanthropic venture arm of the National Bleeding Disorders Foundation, and Sixty Degree Capital.
Seawolf Therapeutics president and CEO Elizabeth Alcamo said: “Seawolf is charting a new course in patient care through LNP-based DNA medicines.
“With a strong syndicate of investors and our collaboration with Sanofi, we are well-positioned to execute on our next stage of growth, which will include advancing our lead programme for metabolic diseases and collaborating with Sanofi in its mission to develop therapies for patient unmet needs.”
Seawolf will use the capital to progress candidates built upon its Targeted RNA-Induced DNA Expression via Nuclear Translocation (TRIDENT) platform.
The technology uses lipid nanoparticles to transport immune-quiet DNA encoding a therapeutic transgene directly into cell nuclei, aided by an auxiliary factor.
This nuclear delivery aims to achieve stable, long-term therapeutic protein expression, overcoming the transient activity associated with standard RNA-based therapies.
Unlike viral vectors, the nanoparticle delivery system allows repeated administration to adjust or supplement dosing over time.
Seawolf showed proof of concept for the approach in preclinical murine and non-human primate models of metabolic and rare diseases.
In addition to collaborating with Sanofi, the company is advancing an internal lead programme targeting metabolic diseases.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.